Opus Genetics (IRD) Enterprise Value (2010 - 2026)
Opus Genetics (IRD) posted quarterly Enterprise Value of -$60.0 million for Q1 2026, down 43.56% year-over-year from -$106.3 million in Q1 2025, and down 33.06% quarter-over-quarter from -$45.1 million in Q4 2025.
Opus Genetics (IRD) Enterprise Value (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported Enterprise Value for 17 consecutive years, with -$60.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 43.56% year-over-year to -$60.0 million; the TTM figure through Mar 2026 stood at -$60.0 million (down 43.56% YoY), while the FY2025 annual figure was -$45.1 million, down 48.7% from the prior year.
- Enterprise Value fell to -$60.0 million in Q1 2026 per IRD's latest filing, from -$45.1 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$14.0 million in Q3 2022 and bottomed at -$60.0 million in Q1 2026.
- Historically, Enterprise Value has averaged -$37.1 million across 5 years, with a median of -$40.0 million in 2023.
- Annual changes were most pronounced in 2023 — Enterprise Value tumbled 203.53% — and 2024, when it surged 39.97%.
- Opus Genetics' Enterprise Value stood at -$42.7 million in 2022, then declined by 18.35% to -$50.5 million in 2023, then soared by 39.97% to -$30.3 million in 2024, then sank by 48.7% to -$45.1 million in 2025, then slumped by 33.06% to -$60.0 million in 2026.
- Business Quant data shows IRD's Enterprise Value at -$60.0 million in Q1 2026, -$45.1 million in Q4 2025, and -$30.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Opus Genetics | 298.36 Mn | 209.55 Mn | - | -88.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -88.81 Mn |
| Mar 31, 2026 | -60.00 Mn |
| Dec 31, 2025 | -45.09 Mn |
| Sep 30, 2025 | -30.82 Mn |
| Jun 30, 2025 | -32.43 Mn |
| Mar 31, 2025 | -41.79 Mn |
| Dec 31, 2024 | -30.32 Mn |
| Sep 30, 2024 | -36.64 Mn |
| Jun 30, 2024 | -41.41 Mn |
| Mar 31, 2024 | -47.21 Mn |
| Dec 31, 2023 | -50.52 Mn |
| Sep 30, 2023 | -42.36 Mn |
| Jun 30, 2023 | -40.02 Mn |
| Mar 31, 2023 | -39.02 Mn |
| Dec 31, 2022 | -42.68 Mn |
| Sep 30, 2022 | -13.96 Mn |
| Jun 30, 2022 | -17.15 Mn |
| Mar 31, 2022 | -19.38 Mn |
| Dec 31, 2021 | -24.75 Mn |
| Sep 30, 2021 | -22.63 Mn |